Background Randomized phase III trials showed interesting, but conflicting results,
regarding the treatment of NSCLC, PS2 population. This meta-analysis aims to review all …

Platinum-based chemotherapy improves long-term survival in patients with advanced non-
small cell lung cancer (NSCLC). Meta-analyses have demonstrated an improvement in …

Introduction. Nearly 40% of patients with advanced NSCLC are in performance status (PS)
2. These patients have a shorter life expectancy than PS 0/1 patients and they are …

The elderly and patients with Performance Status (PS) of 2, constitute the so-called special
patient population. The tolerability of chemotherapy in this population is globally worse, and …

BACKGROUND: There is no consensus regarding chemotherapy to patients with advanced
NSCLC (ANSCLC) and performance status (PS) 2. Using data from a national multicenter …

Background The use of immune checkpoint inhibitors has led to an increase in randomized
controlled trials exploring various first-line combination treatment regimens. With the …

7113 Background: Two phase III trials in chemo-naïve PS2 patients with advanced NSCLC
compared paclitaxel poliglumex (PPX) to either gemcitabine or vinorelbine (STELLAR 4), or …

Introduction A literature review was undertaken to identify clinical trials and real-world
studies of patients with stage IV NSCLC who had progressed on or after treatment with …

Introduction The sole agents pemetrexed (PEM), docetaxel and anti-EGFR agents are
approved second-line therapies for non-small cell lung cancer (NSCLC) after failure with …

Background The major challenge for treating non‐squamous (non‐Sq) non‐small cell lung
cancer (NSCLC) patients without actionable biomarkers is the actual selection of proper …